2026 Q1 -tulosraportti
70 päivää sitten
‧43 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8 t sitten · MuokattuHas anyone else wondered a bit about the wording: “Increasing the lowest number of patients to be included to allow for at least 6 patients dosed with uTREAT® without blood-brain barrier disruption.” The critical detail is the wording “increasing the lowest number” – not “adding a new cohort of 6 patients.” This suggests that patients already exist in this category in the current dataset which they now wish to expand. Of course, there can be other interpretations. But protocol documents are extremely precisely formulated. Every word is thought through by clinical, legal, and regulatory experts. “Increasing the lowest number” is hardly just a poor formulation – it is a legal description of what is actually happening. “Adding a new cohort of at least 6 patients without mannitol” – that would mean that no such patients exist yet. “Increasing the lowest number of patients to be included to allow for at least 6 patients dosed without BBB disruption” – that means that there are already patients in this category, and that the minimum requirement for this group is being increased. (This thread is not a buy or sell recommendation - just a dialogue about what the protocol change really means - we need to get the ultimate answer from Curasight)
Hmm I find this difficult to understand Can't interpret it differently than that it works but does it also work without mannitol?
·18 t sittenIt's really bad communication too, the preliminary results are nothing.. and then they change protocol without disclosing results of the primary study.. One fears a bit that mannitol is damaging something since they want to get rid of it and don't report anything.. if that's the case then brain cancer is a failed strategy.. Have written it before.. they are really bad at leading and communicating.. Still believe in the day.. but as I said when it was at 24.. one should sell the whole damn thing and re-enter later.. because they are really some fuckheads.. But I'm from the countryside.. here you don't sell ... you buy..
One can always discuss that the communication should have been better, but in my head, the whole process makes relatively good sense. These upcoming data are the most important in Curasight's history, and thus it is important to obtain the best possible data. Therefore, they have introduced mannitol to ensure the best possible uptake of Utreat. Since they received additional capital in June (20 Mill dkk), they have assessed that the cheapest and fastest option would be to continue the ongoing study to gain the best possible knowledge about the uptake of Utreat in preparation for phase II trials. Opening the blood-brain barrier with mannitol is not without risk and can cause complications. It is used, for example, if chemotherapy is to be administered. So the complications are known. Thus, it makes good sense to try to remove mannitol, given that they have seen good data from the first 6-12 patients. The whole thing has come a bit late, but they only received additional capital in mid-June, so it makes sense that they have launched this extension here in July due to the extra capital and preparation time for updating the protocol.
·22 t sittenI must say that people are pulling out of this case, and the same with Flouguide. Have they lost faith due to the repeated postponements/changes of the study with longer response times and perhaps a need for new capital, could it be that's what one should do???
And it's also only approx. 0.2% of the shares that are traded daily - so many holdings still believe in the technology
·23 t sittenHasn't Ulrich answered @Zeiler ? They really ought to come with something more detailed soon....?
@AllanL: I'm wondering what you want Ulrich to answer? Dear Zeiler Everything looks really good. Between us two, the topline data is far better than we had hoped for. Just hang in there and buy aggressively, there will be a press release in Q3, which we have already announced. ... or Dear Zeiler Unfortunately, I have to disappoint you, as the topline data is dreadful, and therefore we are now betting the whole store on doing the same thing one more time, just even harder without Mannitol. So hurry up and sell, as we also don't believe it will work. That makes no sense 😂 Mads83 also tried with an email and Ulrich politely replied to it - but naturally nothing new that wasn't publicly known already. The company has announced that topline data is expected in Q3. Until they say otherwise, the assumption is that it is going according to plan. I am probably a bit surprised that we don't have the topline data yet, but they are on their way. Ulrich, on 29/5: "If you look at the stock development, how the stock has developed throughout the year, well, it got a proper push here before Christmas. And we have an expectation and hope that it can reach a new plateau in relation to us hopefully coming out with some good news later in the year"- ·23 t sittenOne wonders, it's not many months since larger investors invested at a price of 19.50. They have certainly been briefed about the future. The price should be around the aforementioned level until data emerges.
Of course, they haven't been told more than we have, that would be highly illegal.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
70 päivää sitten
‧43 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sitten · MuokattuHas anyone else wondered a bit about the wording: “Increasing the lowest number of patients to be included to allow for at least 6 patients dosed with uTREAT® without blood-brain barrier disruption.” The critical detail is the wording “increasing the lowest number” – not “adding a new cohort of 6 patients.” This suggests that patients already exist in this category in the current dataset which they now wish to expand. Of course, there can be other interpretations. But protocol documents are extremely precisely formulated. Every word is thought through by clinical, legal, and regulatory experts. “Increasing the lowest number” is hardly just a poor formulation – it is a legal description of what is actually happening. “Adding a new cohort of at least 6 patients without mannitol” – that would mean that no such patients exist yet. “Increasing the lowest number of patients to be included to allow for at least 6 patients dosed without BBB disruption” – that means that there are already patients in this category, and that the minimum requirement for this group is being increased. (This thread is not a buy or sell recommendation - just a dialogue about what the protocol change really means - we need to get the ultimate answer from Curasight)Hmm I find this difficult to understand Can't interpret it differently than that it works but does it also work without mannitol?
- ·18 t sittenIt's really bad communication too, the preliminary results are nothing.. and then they change protocol without disclosing results of the primary study.. One fears a bit that mannitol is damaging something since they want to get rid of it and don't report anything.. if that's the case then brain cancer is a failed strategy.. Have written it before.. they are really bad at leading and communicating.. Still believe in the day.. but as I said when it was at 24.. one should sell the whole damn thing and re-enter later.. because they are really some fuckheads.. But I'm from the countryside.. here you don't sell ... you buy..One can always discuss that the communication should have been better, but in my head, the whole process makes relatively good sense. These upcoming data are the most important in Curasight's history, and thus it is important to obtain the best possible data. Therefore, they have introduced mannitol to ensure the best possible uptake of Utreat. Since they received additional capital in June (20 Mill dkk), they have assessed that the cheapest and fastest option would be to continue the ongoing study to gain the best possible knowledge about the uptake of Utreat in preparation for phase II trials. Opening the blood-brain barrier with mannitol is not without risk and can cause complications. It is used, for example, if chemotherapy is to be administered. So the complications are known. Thus, it makes good sense to try to remove mannitol, given that they have seen good data from the first 6-12 patients. The whole thing has come a bit late, but they only received additional capital in mid-June, so it makes sense that they have launched this extension here in July due to the extra capital and preparation time for updating the protocol.
- ·22 t sittenI must say that people are pulling out of this case, and the same with Flouguide. Have they lost faith due to the repeated postponements/changes of the study with longer response times and perhaps a need for new capital, could it be that's what one should do???And it's also only approx. 0.2% of the shares that are traded daily - so many holdings still believe in the technology
- ·23 t sittenHasn't Ulrich answered @Zeiler ? They really ought to come with something more detailed soon....?@AllanL: I'm wondering what you want Ulrich to answer? Dear Zeiler Everything looks really good. Between us two, the topline data is far better than we had hoped for. Just hang in there and buy aggressively, there will be a press release in Q3, which we have already announced. ... or Dear Zeiler Unfortunately, I have to disappoint you, as the topline data is dreadful, and therefore we are now betting the whole store on doing the same thing one more time, just even harder without Mannitol. So hurry up and sell, as we also don't believe it will work. That makes no sense 😂 Mads83 also tried with an email and Ulrich politely replied to it - but naturally nothing new that wasn't publicly known already. The company has announced that topline data is expected in Q3. Until they say otherwise, the assumption is that it is going according to plan. I am probably a bit surprised that we don't have the topline data yet, but they are on their way. Ulrich, on 29/5: "If you look at the stock development, how the stock has developed throughout the year, well, it got a proper push here before Christmas. And we have an expectation and hope that it can reach a new plateau in relation to us hopefully coming out with some good news later in the year"
- ·23 t sittenOne wonders, it's not many months since larger investors invested at a price of 19.50. They have certainly been briefed about the future. The price should be around the aforementioned level until data emerges.Of course, they haven't been told more than we have, that would be highly illegal.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
2026 Q1 -tulosraportti
70 päivää sitten
‧43 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sitten · MuokattuHas anyone else wondered a bit about the wording: “Increasing the lowest number of patients to be included to allow for at least 6 patients dosed with uTREAT® without blood-brain barrier disruption.” The critical detail is the wording “increasing the lowest number” – not “adding a new cohort of 6 patients.” This suggests that patients already exist in this category in the current dataset which they now wish to expand. Of course, there can be other interpretations. But protocol documents are extremely precisely formulated. Every word is thought through by clinical, legal, and regulatory experts. “Increasing the lowest number” is hardly just a poor formulation – it is a legal description of what is actually happening. “Adding a new cohort of at least 6 patients without mannitol” – that would mean that no such patients exist yet. “Increasing the lowest number of patients to be included to allow for at least 6 patients dosed without BBB disruption” – that means that there are already patients in this category, and that the minimum requirement for this group is being increased. (This thread is not a buy or sell recommendation - just a dialogue about what the protocol change really means - we need to get the ultimate answer from Curasight)Hmm I find this difficult to understand Can't interpret it differently than that it works but does it also work without mannitol?
- ·18 t sittenIt's really bad communication too, the preliminary results are nothing.. and then they change protocol without disclosing results of the primary study.. One fears a bit that mannitol is damaging something since they want to get rid of it and don't report anything.. if that's the case then brain cancer is a failed strategy.. Have written it before.. they are really bad at leading and communicating.. Still believe in the day.. but as I said when it was at 24.. one should sell the whole damn thing and re-enter later.. because they are really some fuckheads.. But I'm from the countryside.. here you don't sell ... you buy..One can always discuss that the communication should have been better, but in my head, the whole process makes relatively good sense. These upcoming data are the most important in Curasight's history, and thus it is important to obtain the best possible data. Therefore, they have introduced mannitol to ensure the best possible uptake of Utreat. Since they received additional capital in June (20 Mill dkk), they have assessed that the cheapest and fastest option would be to continue the ongoing study to gain the best possible knowledge about the uptake of Utreat in preparation for phase II trials. Opening the blood-brain barrier with mannitol is not without risk and can cause complications. It is used, for example, if chemotherapy is to be administered. So the complications are known. Thus, it makes good sense to try to remove mannitol, given that they have seen good data from the first 6-12 patients. The whole thing has come a bit late, but they only received additional capital in mid-June, so it makes sense that they have launched this extension here in July due to the extra capital and preparation time for updating the protocol.
- ·22 t sittenI must say that people are pulling out of this case, and the same with Flouguide. Have they lost faith due to the repeated postponements/changes of the study with longer response times and perhaps a need for new capital, could it be that's what one should do???And it's also only approx. 0.2% of the shares that are traded daily - so many holdings still believe in the technology
- ·23 t sittenHasn't Ulrich answered @Zeiler ? They really ought to come with something more detailed soon....?@AllanL: I'm wondering what you want Ulrich to answer? Dear Zeiler Everything looks really good. Between us two, the topline data is far better than we had hoped for. Just hang in there and buy aggressively, there will be a press release in Q3, which we have already announced. ... or Dear Zeiler Unfortunately, I have to disappoint you, as the topline data is dreadful, and therefore we are now betting the whole store on doing the same thing one more time, just even harder without Mannitol. So hurry up and sell, as we also don't believe it will work. That makes no sense 😂 Mads83 also tried with an email and Ulrich politely replied to it - but naturally nothing new that wasn't publicly known already. The company has announced that topline data is expected in Q3. Until they say otherwise, the assumption is that it is going according to plan. I am probably a bit surprised that we don't have the topline data yet, but they are on their way. Ulrich, on 29/5: "If you look at the stock development, how the stock has developed throughout the year, well, it got a proper push here before Christmas. And we have an expectation and hope that it can reach a new plateau in relation to us hopefully coming out with some good news later in the year"
- ·23 t sittenOne wonders, it's not many months since larger investors invested at a price of 19.50. They have certainly been briefed about the future. The price should be around the aforementioned level until data emerges.Of course, they haven't been told more than we have, that would be highly illegal.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt